 <h1>Zaltrap Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ziv-aflibercept</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ziv-aflibercept. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Zaltrap.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ziv-aflibercept: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ziv-aflibercept (the active ingredient contained in Zaltrap) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ziv-aflibercept:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>bloody nose</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>decreased urination</li>
<li>difficult, burning, or painful urination</li>
<li>dizziness or lightheadedness</li>
<li>dry mouth</li>
<li>excessive thirst</li>
<li>fainting</li>
<li>fever or chills</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>nervousness</li>
<li>pain or swelling around the rectum</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sudden shortness of breath or troubled breathing</li>
<li>sunken eyes</li>
<li>swollen glands</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>voice changes</li>
<li>wrinkled skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Pains in the chest, groin, or legs, especially calves of the legs</li>
<li>severe headaches of sudden onset</li>
<li>sudden loss of coordination</li>
<li>sudden onset of shortness of breath for no apparent reason</li>
<li>sudden onset of slurred speech</li>
<li>sudden vision changes</li>
<li>troubled breathing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Heartburn</li>
<li>indigestion</li>
<li>nausea</li>
<li>severe abdominal or stomach pain, cramping, or burning</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Dilated neck veins</li>
<li>extreme fatigue</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ziv-aflibercept may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>lack or loss of strength</li>
<li>redness, swelling, or pain of the skin</li>
<li>runny nose</li>
<li>scaling of the skin on the hands and feet</li>
<li>swelling or inflammation of the mouth</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Heavy jaw feeling</li>
<li>loosening of a tooth</li>
<li>pain, swelling, or numbness in the mouth or jaw</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ziv-aflibercept: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (41%)</p>
<p><b>Common</b> (1% to 10%): Arterial thromboembolic events (ATE) (e.g., transient ischemic attack, cerebrovascular accident, angina pectoris)</p>
<p><b>Postmarketing reports</b>: Cardiac failure, ejection fraction decreased<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (11%)</p>
<p><b>Common</b> (1% to 10%): Skin hyperpigmentation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (69%), stomatitis (50%), abdominal pain (27%), abdominal pain upper (11%)</p>
<p><b>Common</b> (1% to 10%): Fistulas (anal, enterovesical, enterocutaneous, colovaginal, intestinal sites), dehydration, oropharyngeal pain, hemorrhoids, rectal hemorrhage, proctalgia</p>
<p><b>Uncommon</b> (0.1% to 1%): GI hemorrhage, toothache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (78%), neutropenia (67%), thrombocytopenia (35%), hemorrhage (38%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (46%)</p>
<p><b>Common</b> (1% to 10%): Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (32%), weight loss (32%)</p>
<p><b>Postmarketing reports</b>: Osteonecrosis of the jaw<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (48%), dysphonia (25%), asthenia (18%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Compromised wound healing<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Proteinuria (62%), serum creatinine increased (23%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (28%), dyspnea (12%)</p>
<p><b>Common</b> (1% to 10%): Rhinorrhea, nasopharyngitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (62%), ALT increased (50%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Zaltrap (ziv-aflibercept)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>1 Review</li>
<li>Drug class: VEGF/VEGFR  inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zaltrap &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ziv-aflibercept: intravenous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (41%)</p><p><b>Common</b> (1% to 10%): Arterial thromboembolic events (ATE) (e.g., transient ischemic attack, cerebrovascular accident, angina pectoris)</p><p><b>Postmarketing reports</b>: Cardiac failure, ejection fraction decreased<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Palmar-plantar erythrodysesthesia syndrome (11%)</p><p><b>Common</b> (1% to 10%): Skin hyperpigmentation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (69%), stomatitis (50%), abdominal pain (27%), abdominal pain upper (11%)</p><p><b>Common</b> (1% to 10%): Fistulas (anal, enterovesical, enterocutaneous, colovaginal, intestinal sites), dehydration, oropharyngeal pain, hemorrhoids, rectal hemorrhage, proctalgia</p><p><b>Uncommon</b> (0.1% to 1%): GI hemorrhage, toothache<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (78%), neutropenia (67%), thrombocytopenia (35%), hemorrhage (38%)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (46%)</p><p><b>Common</b> (1% to 10%): Immunogenicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (32%), weight loss (32%)</p><p><b>Postmarketing reports</b>: Osteonecrosis of the jaw<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (22%)</p><p><b>Uncommon</b> (0.1% to 1%): Reversible posterior leukoencephalopathy syndrome (RPLS)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (48%), dysphonia (25%), asthenia (18%)</p><p><b>Uncommon</b> (0.1% to 1%): Compromised wound healing<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Proteinuria (62%), serum creatinine increased (23%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (28%), dyspnea (12%)</p><p><b>Common</b> (1% to 10%): Rhinorrhea, nasopharyngitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): AST increased (62%), ALT increased (50%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ. </p><h2>More about Zaltrap (ziv-aflibercept)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>1 Review</li>
<li>Drug class: VEGF/VEGFR  inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Zaltrap &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Colorectal Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>